Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

SRT1720 HCl

For research use only.

Catalog No.S1129

130 publications

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 2470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SRT1720 HCl has been cited by 130 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  NIfyUXFHfW6ldHnvckBCe3OjeR?= MVi0xsDPxE1? NWj5NGtPOzEEoH3pci=> M4PocGROW09? MUTpcoR2[2W|IHHjeZRmKFOLUmSxJIFkfGm4YYTpc47DqA>? NYL3U4w5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVQyODRpPkK2NlU1OTB2PD;hQi=>
MC3T3-E1 M3PYcGZ2dmO2aX;uJGF{e2G7 NYjDS3NVOTBiwsXNxsA> NIHlbmUyKGh? M3PJdZJm\HWlZYOgeIhmKFSJRj5Otk1{fGmvdXzheIVlKF[HR1[gdoVt\WG|ZTDpckBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{wrC= NFLUbXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlk4QCd-Mk[xN|Y6Pzh:L3G+
MC3T3-E1 MWXGeY5kfGmxbjDBd5NigQ>? NUHYcoZOOTBiwsXNxsA> NI\0[|kyOiCq MWTy[YR2[2W|IITo[UBXTUeIIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMhe3SrbYXsZZRm\CCkeTDUS2Yu|rJ? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|Nkm3PEc,OjZzM{[5O|g9N2F-
MC3T3-E1 Ml;rSpVv[3Srb36gRZN{[Xl? MkDjNlAh|ryP MlrtNUBp M1TrXpN2eHC{ZYPz[ZMhfGinIGTHSk3Pui2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2Vib4KgV2FRUy:MTlu= NX;pO5JSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|Y6PzhpPkK2NVM3QTd6PD;hQi=>
WE-68 M{XHZWFxd3C2b4Ppd{BCe3OjeR?= MWWwMVI1KM7:TR?= NGOxemkzPCCq MkTmbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-ES-1 MVPBdI9xfG:|aYOgRZN{[Xl? M4LLclAuOTBizszN MXSyOEBp M2O4dolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCmb4PlJIRmeGWwZHXueIx6 NH3JTIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
SK-N-MC  MnnXRZBweHSxc3nzJGF{e2G7 Mn3mNE0zNjVizszN NFq5XmYzPCCq NFrpSnFqdmS3Y3XzJINmdGxiZHXheIghcW5iZH;z[UBl\XCnbnTlcpRtgQ>? NIPod2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
WE-68 NEO5TppHfW6ldHnvckBCe3OjeR?= NHP0V2EzOCEQvF2= MWqwMVI1KGh? NEHoc4di[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? NYXyeI11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-ES-1 MoXaSpVv[3Srb36gRZN{[Xl? NETncmMyOCEQvF2= MoPjNE0zPCCq NYTXWJRP[WO2aY\heIV{KGOjc4Dhd4UhOy95 NUfqRW11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-N-MC  NYm0OlJETnWwY4Tpc44hSXO|YYm= MoXUN{DPxE1? MWGwMVI1KGh? MYfhZ5RqfmG2ZYOgZ4F{eGG|ZTCzM|c> NIe2UHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVgxPSd-Mk[wOVU5ODV:L3G+
NRK-49F Mk\2SpVv[3Srb36gRZN{[Xl? NF7wSIIx6oDVMtMg{txO MVSzOkBp MWrpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iEQsT3TUWEh[W6mIH\pZpJwdmWldHnuJIRwe2ViZHXw[Y5l\W62bIm= MorZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F M1fOTWZ2dmO2aX;uJGF{e2G7 NHr0NZkx6oDVMtMg{txO NGG1fmo{PiCq NWHZR2gy\W6qYX7j[ZMheGixc4Doc5J6dGG2aX;uJI9nKEWJRmKgZY5lKFCGR1\S{tLDqA>? NI\JT5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyNlAxOyd-Mk[wNlIxODN:L3G+
NRK-49F NUHvbmNWTnWwY4Tpc44hSXO|YYm= NFrkcZYx6oDVMtMg{txO NUCweHM6OzZiaB?= MnPq[Y5p[W6lZYOgV3RCXDNicHjvd5Bpd3K7bHH0bY9v NYnFeXZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
RAW264.7 NWTlNYpJTnWwY4Tpc44hSXO|YYm= MU[xJO69VQ>? NVLjWJh1PiCq NVSwfolPfXC{ZXf1cIF1\XNidHjlJJJm\HWlZXSgV2lTXDFicILveIVqdiCxcjDtVm5CKGyndnXsd{BjgSCqaXfoJIdtfWOxc3W= MkPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OUO5PVUoRjJ3N{mzPVk2RC:jPh?=
MCF10A MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInTPFExNTJyIN88US=> M1frXVI1KGh? MVry[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M1fDXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MCF-7 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnIZ5UxNTJyIN88US=> NILPT2kzPCCq M4TI[JJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
T47D NWDuRZFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PCfVAuOjBizszN MWmyOEBp NHfxdJRz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MnjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
SKBR3 NHL1T5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S0eFAuOjBizszN NYS5VHBUOjRiaB?= NVHVVYN{emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NI\Wfok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MDA-MB-231 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[wUlkxNTJyIN88US=> MXSyOEBp NGG4SG5z\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHjoV3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
SUM149 NX;SWYoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPUR5drOC1{MDFOwG0> MXGyOEBp M1jufpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MmDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
HS578T M{L5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILoSJAxNTJyIN88US=> MofwNlQhcA>? NFPOdmdz\WS3Y3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
BT20 Mm\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPtNE0zOCEQvF2= NWXBfHg4OjRiaB?= MnLidoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M3fNVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
A459 NWizfGZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVywMVIxKM7:TR?= MVSyOEBp MYXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M1LnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
HCT116 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVWwMVIxKM7:TR?= MlvWNlQhcA>? M3;3[pJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M2jxbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
Neu MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrJNE0zOCEQvF2= MlO2NlQhcA>? MVLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NVS2XJJ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
MDA-MB-231 NU\MVVVETnWwY4Tpc44hSXO|YYm= M{LDUlUh|ryP NVSxZo5RQCCq NX7mNoVvcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gZYNq\GmlII\ld4lkfWyjcjDvdodidmWubHXz MlSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MDA-MB-231 Mnv3SpVv[3Srb36gRZN{[Xl? NUiwUlF6PSEQvF2= NHrHNYMyPiCq NU[ybId[cW6mdXPld{BtgXOxc3;tZYwhdWWvYoLhcoUheGW{bXXhZoltcXqjdHnvci=> Moi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MC3T3-E1 MlrNSpVv[3Srb36gRZN{[Xl? M{jxSVExKM7:TR?= M17oZ|YxKG2rbtMg MVvzeZBxemW|c3XzJJRp\SCIR1[tNk1{fGmvdXzheIVlKG:|dHXvdJJwfGWpZYLpckBz\WynYYPl NEHKTGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1 NV63XXNqTnWwY4Tpc44hSXO|YYm= NGDM[VMyOCEQvF2= NGXiSJU3OCCvaX9CpC=> MoHDZZR1\W63YYTld{B1cGViRlfGMVIucW6mdXPl[EBwe3Snb4Dyc5Rm\2W{aX6gcXJPSSCneIDy[ZN{cW:w M2nkU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkmwNFk2Lz5{NUK5NFA6PTxxYU6=
MC3T3-E1 NXOx[5djTnWwY4Tpc44hSXO|YYm= MoLvNVAh|ryP MVK2NEBucW8EoB?= NWThfFNC[XS2ZX71ZZRmeyC2aHWgSmdHNTJvaX7keYNm\CCxc4Tlc5Bzd3SnZ3XybY4hdVKQQTDlfJBz\XO|aX;u NHXyOmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1 M323V2Z2dmO2aX;uJGF{e2G7 MmfoNVAh|ryP MlvlOlAhdWmwwrC= NYPTfnlRe3WycILld5NmeyC2aHWgRm1RNTRvc4TpcZVt[XSnZDDWSWdHKHKnbHXhd4U> MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR|NUS0OEc,OjR2M{W0OFQ9N2F-
MC3T3-E1 MYfGeY5kfGmxbjDBd5NigQ>? M{XLe|ExKM7:TR?= NEP2blQ3OCCvaX9CpC=> NIPsTY1{fXCycnXzd4V{KHSqZTDQS2Yz|rFvc4TpcZVt[XSnZDDPVGchemWuZXHz[S=> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN|M{OzOkc,OjR|M{OzN|Y9N2F-
MC3T3-E1 NEL6WYtHfW6ldHnvckBCe3OjeR?= MofjNVAh|ryP NEfFdJc3OCCvaX9CpC=> M1LBNpJm\HWlZYOgeIhmKFCJRkNOtU1{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2V? NHHLcZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
MC3T3-E1 MUPGeY5kfGmxbjDBd5NigQ>? Mn;PNVAh|ryP NUjIUodSPjBibXnuxsA> MmfiZZR1\W63YYTld{B1cGViUFfGNu6yNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigUWVMOS9{IHHu[EBT[WZvMR?= MlnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
RPE MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NF\jUIk2KML3TR?= NWjWPG5vOSCq NEXxNYpifHSnboXheIV{KE:DzsKtbY5lfWOnZDDk[YNz\WG|ZTDv[kBk\WyuII\pZYJqdGm2eR?= NEDaZ3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzOlk{QCd-MkSwN|Y6Ozh:L3G+
9607 NGLKfoNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2PPT|Eh|ryP NYLzOFVEOzZiaB?= MXTpcoNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwdXCjcnXkJJdqfGhibXXsZZRwdmmwIHHsc45m NYXab4hzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NlY6PDlpPkKzO|I3QTR7PD;hQi=>
9607 NGnQe2RHfW6ldHnvckBCe3OjeR?= MkixNUDPxE1? MVizOkBp M2D6VYlv[3KnYYPld{BUUVKWMTDhcoQh\GWlcnXhd4VlKGGlZYT5cIF1\WRvcEWzJIV5eHKnc4Ppc44> NGLicYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlk1QSd-MkO3NlY6PDl:L3G+
RPMI.8226 MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjoO{8yOCEQvF2= MUiyOEBp Mnrw[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 M{O3Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
U266 M1L2V2NmdGxiVnnhZoltcXS7IFHzd4F6 M{XPcVcwOTBizszN MkO3NlQhcA>? MlK4[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NH;mXmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
MM.1S MWnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFzCWWI4NzFyIN88US=> M4nofVI1KGh? M4PGcIRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
KMS12 MmfxR4VtdCCYaXHibYxqfHliQYPzZZk> NGnCb4Y4NzFyIN88US=> M{DWUlI1KGh? NV;yU4gx\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MlHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
LR5 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWe3M|ExKM7:TR?= NHLnPGUzPCCq MYLk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1R MWHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWX1PWNPPy9zMDFOwG0> NILWR5AzPCCq NEPYSppl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> NXTGTXJCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
Ina6 MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zuUlcwOTBizszN NFjZRngzPCCq M2TtS4Rm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NV3qXZl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
RPMI-8226 Mnm1RZBweHSxc3nzJGF{e2G7 NH\hXGI4NzFyIN88US=> MWmyOEBp M2XCUolv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjD0bIUhSW6wZYjpckBXMy:SSfMIluKh[XCxcITvd4l{ MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1R  NXfxXmVNSXCxcITvd4l{KEG|c3H5 MnjrO{8yOCEQvF2= Mk\iNlQhcA>? Mn;obY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> NX36XVJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
H411EC3 M2\NVWZ2dmO2aX;uJGF{e2G7 MVO1NE8yODBibl2= NIjRN|E3KGh? MYjpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M3u5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
hepatocytes NFG5d|BHfW6ldHnvckBCe3OjeR?= M2DKUVExKG6P MV22JIg> MWLpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> M1q4WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
hepatocytes NFq5R3lHfW6ldHnvckBCe3OjeR?= MVuxNEBvVQ>? M2SwflYhcA>? MXHpcoNz\WG|ZYOgTI1o[3MEoHHu[OKhSWOlwrDn[Y5mKGW6cILld5Nqd25? M{nwV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
U2OS MY\GeY5kfGmxbjDhd5NigQ>? MUmwMlExKHWP M{\jN2FkfGm4YYTpc44hd2ZiU1nSWFEhcW5iaIXtZY4hXTKRUzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBxPTNiZHXhZ4V1gWyjdHnvckBt\X[nbDDheEAxNjFyIIXN NGn2RWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC0OlQxQSd-MUiwOFY1ODl:L3G+
A673 M3Sy[pFJXFNiYYPzZZk> MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? NWXs[5l5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NXrGTYJieUiWUzDhd5NigQ>? MnnIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 MXvxTHRUKGG|c3H5 NXfFPW5CeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz NHy0TmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MYHxTHRUKGG|c3H5 M13jR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? NFjLRWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NWfPW|VweUiWUzDhd5NigQ>? NX7VXI1DeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz M3K1TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MWfxTHRUKGG|c3H5 MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NFPnS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MU\xTHRUKGG|c3H5 Mm\mdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= MkC2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 Mn61dWhVWyCjc4PhfS=> NVzmSm5veUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NHHVUWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NHS1eYVyUFSVIHHzd4F6 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? NYrGSnpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MVPxTHRUKGG|c3H5 Mnq4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| NX;DW4d6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 MYDxTHRUKGG|c3H5 NHjj[mJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnixPEBk\Wyucx?= NFix[JI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1; 

PubMed: 26655844     


SU86.86 cells were transfected with control siRNA, SIRT1 siRNA#1, or DBC1 siRNA. 24 hours after transfection, cells were re-plated and allowed to attach for 24 hours. Cells were then treated with vehicle (control) or 5 μM SRT1720 for 16 hours. Expression 䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙

26655844
Immunofluorescence
Cathepsin B; 

PubMed: 26655844     


SU86.86 cells were incubated with vehicle or 5 μM SRT1720 for 5 hours for LysoTracker Red labeling and 16 hours for cathepsin B immunofluorescence, followed by DAPI staining.

26655844
Growth inhibition assay
Cell viability ; 

PubMed: 25411356     


MTT viability assay of cancer cell lines treated with different doses of SRT1720 for 24 hours. 

25411356
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
- Collapse

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
- Collapse
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • Answer:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID